充血性心臟衰竭 (CHF) 治疗设备市场 - 副产品（除颤器、起搏器、心臟再同步治疗设备、心室辅助设备）、最终用途（医院、心臟诊所） - 全球预测 2024 - 2032 年

Congestive Heart Failure (CHF) Treatment Devices Market - By Product (Defibrillator, Pacemaker, Cardiac Resynchronization Therapy Device, Ventricular Assist Device ), End-use (Hospital, Cardiac Clinic) - Global Forecast 2024 - 2032

出版日期: 2024年01月31日 | 出版商:

Global Market Insights Inc. | 英文 440 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于心律调节器、植入式心律转復除颤器(ICD) 和心臟再同步治疗(CRT) 设备的使用不断增加，加上连续治疗，2024 年至2032 年间，全球充血性心臟衰竭(CHF)治疗设备市场CAGR将以 6.4% 的复合年增长率成长。新技术的监管批准。慢性心臟衰竭治疗设备的不断创新正在提高疗效和患者治疗效果，以满足不断变化的患者需求。新型设备的引入也增强了治疗选择，从而提高了产品采用率并扩大了市场。

例如，2022年12月，雅培在印度推出了最新的经导管主动脉瓣植入（TAVI）系统Navitor，为手术风险较高的严重主动脉瓣狭窄患者提供微创解决方案。此次推出将先进的治疗选择扩展到更广泛的人群，以更有效地解决心臟瓣膜疾病。

CHF 治疗设备产业根据产品、最终用途和地区而分散。

根据产品，起搏器领域的市场价值到 2032 年将实现 4.5% 的CAGR，这归因于广泛用于治疗与心臟衰竭相关的心律不整和心律不整。心律调节器在调节心律、改善CHF患者心臟功能方面发挥着至关重要的作用。随着心律调节器技术的进步，例如远端监控和可编程性，心律调节器的采用将进一步增长，因为它们在管理充血性心臟衰竭症状方面的有效性和多功能性。

从 2024 年到 2032 年，心臟诊所领域的充血性心臟衰竭治疗设备产业规模将增加 6.5%。这是由于专注于 CHF 管理的专业心臟诊所数量不断增加而推动的。心臟诊所通常采用多学科方法，利用一系列设备，例如起搏器、植入式心律转復除颤器 (ICD) 和心臟再同步治疗 (CRT) 设备。对专业护理和创新治疗的日益重视将促进该细分市场的成长。

在心血管疾病盛行率上升、老年人口增加和医疗基础设施改善的推动下，亚太地区 2024 年至 2032 年 CHF 治疗设备市场的CAGR将达到 8.3%。中国、日本和印度等国家造成了瑞士心臟衰竭病例的沉重负担。此外，越来越多地采用先进治疗设备和政府改善心臟护理的措施将进一步加强该地区的市场发展。

产业生态系统分析
产业影响力
- 成长动力
  - 心臟衰竭和心血管疾病的盛行率上升
  - 技术进步与创新设备的引进
  - 有利的报销方案
  - 提高对心臟衰竭治疗的认识
- 产业陷阱与挑战
  - 设备成本高
  - 产品召回
成长潜力分析
波特的分析
PESTEL分析
2023 年定价分析
2023 年全球及区域心臟衰竭人数
报销场景
监管环境
技术景观
管道产品
未来市场趋势
缺口分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

主要趋势
除颤器
- 植入式心臟復律去颤器 (ICD)
  - 经静脉ICD
    - 单腔 ICD
    - 双腔 ICD
  - 皮下ICD
- 体外心臟復律去颤器
  - 手动体外心臟去颤器
  - 自动体外心臟去颤器
    - 半自动体外心臟去颤器
    - 全自动体外心臟去颤器
  - 穿戴式体外心臟復律去颤器
起搏器
- 植入式心律调节器
- 体外心律调节器
心臟再同步治疗装置
- 心臟再同步治疗-去颤器 (CRT-D)
  - MRI 相容于 CRT-D 设备
  - 传统 CRT-D 设备
- 心臟再同步治疗-节律器 (CRT-P)
  - MRI 相容于 CRT-P 设备
  - 传统 CRT-P 设备
心室辅助装置 (VAD)
- 左心室辅助装置 (LVAD)
- 右心室辅助装置 (RVAD)
- 双心室辅助装置 (BIVAD)
- 经皮心室辅助装置 (PVAD)
- 全人工心臟
其他产品

第 6 章：市场估计与预测：依最终用途，2018 - 2032 年

主要趋势
医院
心臟诊所
门诊手术中心
其他最终用户

第 7 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 8 章：公司简介

Abbott Laboratories
Biotronik SE & Co. KG
Boston Scientific Corporation
Koninkilijke Philips N.V.
Lepu Medical Technology Co. Ltd.
LivaNova PLC
MEDICO S.p.A.
Medtronic plc
MicroPort Scientific Corporation
OSCOR Inc.
Schiller AG
Shree Pacetronix Ltd.
St. Jude Medical, Inc.
Stryker Corporation
Terumo Corporation

简介目录

Product Code: 7994

Global Congestive Heart Failure (CHF) Treatment Devices Market size will grow at a 6.4% CAGR between 2024 and 2032, owing to the rising usage of pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices coupled with continuous regulatory approvals of new technologies. Rising innovations in CHF treatment devices are offering improved effectiveness and patient outcomes for meeting the evolving patient needs. The introduction of novel devices is also enhancing the treatment options, leading to increased product adoption and market expansion.

For instance, in December 2022, Abbott introduced Navitor, its latest transcatheter aortic valve implantation (TAVI) system, in India, for offering a minimally invasive solution for severe aortic stenosis patients at high surgical risk. This launch extends advanced treatment options to a broader population for addressing heart valve diseases more effectively.

The CHF treatment devices industry is fragmented on the basis of product, end-use, and region.

Based on product, the market value from the pacemaker segment will witness 4.5% CAGR up to 2032, attributed to the widespread use in managing CHF-related arrhythmias and heart rhythm disorders. Pacemakers play a crucial role in regulating heart rhythms and improving cardiac function in CHF patients. With advancements in pacemaker technology, such as remote monitoring and programmability, the adoption of pacemakers will further grow due to their effectiveness and versatility in managing CHF symptoms.

Congestive heart failure treatment devices industry size from the cardiac clinic segment will garner 6.5% gains from 2024 to 2032. This is propelled by the increasing number of specialized cardiac clinics focusing on CHF management. Cardiac clinics often adopt a multidisciplinary approach, utilizing a range of devices such as pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. The growing emphasis on specialized care and innovative treatments will add to the segment growth.

Asia Pacific will secure an 8.3% CAGR in the CHF treatment devices market during 2024 and 2032, driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, and improving healthcare infrastructure. Countries like China, Japan, and India are significantly contributing to a high burden of CHF cases. Moreover, the growing adoption of advanced treatment devices and government initiatives to improve cardiac care will further strengthen the market development in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & working
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of heart failure and cardiovascular diseases
  - 3.2.1.2 Technological advancements and introduction of innovative devices
  - 3.2.1.3 Favorable reimbursement scenario
  - 3.2.1.4 Increasing awareness regarding heart failure treatment
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of devices
  - 3.2.2.2 Product recalls
3.3 Growth potential analysis
3.4 Porter's analysis
- 3.4.1 Supplier power
- 3.4.2 Buyer power
- 3.4.3 Threat of new entrants
- 3.4.4 Threat of substitutes
- 3.4.5 Industry rivalry
3.5 PESTEL analysis
3.6 Pricing analysis, 2023
3.7 Number of heart failures at global and regional, 2023
3.8 Reimbursement scenario
3.9 Regulatory landscape
3.10 Technological landscape
3.11 Pipeline products
3.12 Future market trends
3.13 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Defibrillators
- 5.2.1 Implantable cardioverter defibrillators (ICDs)
  - 5.2.1.1 Transvenous ICD
    - 5.2.1.1.1 Single-chamber ICDs
    - 5.2.1.1.2 Dual-chamber ICDs
  - 5.2.1.2 Subcutaneous ICD
- 5.2.2 External cardioverter defibrillator
  - 5.2.2.1 Manual external defibrillator
  - 5.2.2.2 Automated external defibrillator
    - 5.2.2.2.1 Semi-automated external defibrillator
    - 5.2.2.2.2 Fully automated external defibrillator
  - 5.2.2.3 Wearable external cardioverter defibrillator
5.3 Pacemakers
- 5.3.1 Implantable pacemakers
- 5.3.2 External pacemakers
5.4 Cardiac resynchronization therapy devices
- 5.4.1 Cardiac resynchronization therapy-defibrillators (CRT-D)
  - 5.4.1.1 MRI compatible CRT-D devices
  - 5.4.1.2 Conventional CRT-D devices
- 5.4.2 Cardiac resynchronization therapy-pacemakers (CRT-P)
  - 5.4.2.1 MRI Compatible CRT-P devices
  - 5.4.2.2 Conventional CRT-P devices
5.5 Ventricular assist devices (VADs)
- 5.5.1 Left ventricular assist devices (LVADs)
- 5.5.2 Right ventricular assist devices (RVADs)
- 5.5.3 Biventricular assist devices (BIVADs)
- 5.5.4 Percutaneous ventricular assist devices (PVADs)
- 5.5.5 Total artificial heart
5.6 Other products

Chapter 6 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospitals
6.3 Cardiac clinics
6.4 Ambulatory surgical centers
6.5 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Italy
- 7.3.5 Spain
- 7.3.6 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 Saudi Arabia
- 7.6.2 South Africa
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa